Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Jan 2017
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the intravenously administered pan-PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. ⋯ NCT01404390.